We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Ingestible Pill-Sized Device Safely Monitors Vital Signs from Within Patient’s GI Tract

By HospiMedica International staff writers
Posted on 22 Nov 2023

In recent years, scientists have made significant strides in developing a range of ingestible devices. These devices, unlike implantable ones such as pacemakers, offer ease of use without the need for surgical procedures. An example of this technology in action is the use of pill-sized cameras for non-invasive colonoscopies. Building upon this concept, scientists have now introduced an innovative ingestible device designed to monitor vital signs like heart rate and breathing from within the body. This device shows potential for offering convenient care for individuals at risk of opioid overdose.

Created by Celero Systems (Lincoln, MA, USA), the vitals-monitoring pill (VM Pill) functions by detecting the subtle vibrations produced by heartbeat and respiratory movements. It is especially useful in identifying breathing cessation, a critical condition often associated with opioid overdoses, from within the digestive tract. To validate the effectiveness of the VM Pill, it was tested in anesthetized pigs. The pigs received a dose of fentanyl to simulate the conditions of an overdose, causing them to stop breathing. Remarkably, the pill successfully monitored the pigs' breathing rates in real-time, allowing researchers to intervene and reverse the overdose effects.


Image: VMPill shown in a clear gel capsule for ease of visualization of internal components (Photo courtesy of Ben Pless)
Image: VMPill shown in a clear gel capsule for ease of visualization of internal components (Photo courtesy of Ben Pless)

The VM Pill was also trialed in humans for the first time with individuals undergoing sleep apnea evaluations. It effectively detected pauses in breathing and tracked respiration rates with a 92.7% accuracy rate. When compared to external monitoring devices, this pill showed at least 96% accuracy in heart rate monitoring. The trials confirmed the pill's safety, with participants naturally excreting the device within a few days post-experiment. Currently, the VM Pill is designed to pass through the body in about a day, but future enhancements aim to extend its duration in the body for more prolonged monitoring. Additionally, there are plans to upgrade the pill to automatically administer medication in response to detected conditions like opioid overdose.

“The idea of using an ingestible device is that a physician can prescribe these capsules, and all the patient needs to do is to swallow it,” said Benjamin Pless, the founder of Celero Systems. “People are accustomed to taking pills, and costs of using ingestible devices are much more affordable than performing traditional medical procedures.”

Related Links:
Celero Systems


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Gold Member
X-Ray QA Meter
T3 AD Pro
New
Mini C-arm Imaging System
Fluoroscan InSight FD
New
Diagnostic Ultrasound System
MS1700C

Latest Critical Care News

Ablation Treatment Better Than Medication for Heart Attack Survivors

Cranial Accelerometry Headset Enables Timely and Accurate Prehospital Detection of LVO Strokes

Ingestible Capsule Pump Drugs Directly into Walls of GI Tract